Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

Inclusion Criteria:

* Voluntary written informed consent form.
* Histologically or cytologically confirmed advanced malignant solid tumors.
* Measurable or non-measurable disease following (RECIST)
* Age ≥ 18 years.
* Life expectancy ≥ 3 months.
* Performance status ECOG ≤ 2.
* Recovery from any drug-related adverse events (AEs) derived from previous treatments.
* Appropriate bone marrow, liver and renal function.
* Left ventricular ejection fraction (LVEF) within normal limits for the institution.
* Women of childbearing potential must have a negative serum pregnancy test before study entry. Both men and women must agree to use a medically acceptable method of contraception throughout the treatment period and for three months after discontinuation of treatment.

Exclusion Criteria:

* Prior therapy with PM02734.
* Pregnant or lactating women.
* Less than four weeks from radiation therapy.
* Evidence of progressive central nervous system (CNS) metastases. or any symptomatic brain or leptomeningeal metastases.
* Other relevant diseases or adverse clinical conditions.
* Any other major illness that, in the Investigator's judgment.
* Limitation of the patient's ability to comply with the treatment or to follow-up at a participating protocol.
* Ingestion of potent cytochrome CYP3A4 inhibitors.
* Treatment with any investigational product in the 30-day period prior to the first infusion.
* Known hypersensitivity to any component of PM02734 or erlotinib.